Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C5H14NO.C4H5O6 |
Molecular Weight | 253.2497 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C[N+](C)(C)CCO.O[C@H]([C@@H](O)C([O-])=O)C(O)=O
InChI
InChIKey=QWJSAWXRUVVRLH-LREBCSMRSA-M
InChI=1S/C5H14NO.C4H6O6/c1-6(2,3)4-5-7;5-1(3(7)8)2(6)4(9)10/h7H,4-5H2,1-3H3;1-2,5-6H,(H,7,8)(H,9,10)/q+1;/p-1/t;1-,2-/m.1/s1
Molecular Formula | C4H6O6 |
Molecular Weight | 150.0868 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | C5H13NO |
Molecular Weight | 103.1628 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/19906248Curator's Comment: description was created based on several sources, including
https://clinicaltrials.gov/ct2/show/NCT02669641 | https://clinicaltrials.gov/ct2/show/NCT01098383 | https://clinicaltrials.gov/ct2/show/NCT00720343 | https://www.ncbi.nlm.nih.gov/pubmed/15213044 | https://www.ncbi.nlm.nih.gov/pubmed/28152052
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19906248
Curator's Comment: description was created based on several sources, including
https://clinicaltrials.gov/ct2/show/NCT02669641 | https://clinicaltrials.gov/ct2/show/NCT01098383 | https://clinicaltrials.gov/ct2/show/NCT00720343 | https://www.ncbi.nlm.nih.gov/pubmed/15213044 | https://www.ncbi.nlm.nih.gov/pubmed/28152052
CHOLINE is a basic constituent of lecithin that is found in many plants and animal organs. Choline was officially recognized as an essential nutrient by the Institute of Medicine in 1998.1 Its role in the body is complex. It is needed for neurotransmitter synthesis (acetylcholine), cell-membrane signaling (phospholipids), lipid transport (lipoproteins), and methyl-group metabolism (homocysteine reduction). It is the major dietary source of methyl groups via the synthesis of S-adenosylmethionine (AdoMet). At least 50 AdoMet-dependent reactions have been identified in mammals, and it is likely that the number is much higher. Choline is required to make the phospholipids phosphatidylcholine, lysophosphatidylcholine, choline plasmalogen, and sphingomyelin—essential components for all membranes. It plays important roles in brain and memory development in the fetus and appears to decrease the risk of the development of neural tube defects. The importance of choline in the diet extends into adulthood and old age. In a study of healthy adult subjects deprived of dietary choline, 77% of the men and 80% of the postmenopausal women developed signs of subclinical organ dysfunction (fatty liver or muscle damage). Less than half of premenopausal women developed such signs. Ten percent of the subjects studied developed fatty liver, muscle damage, or both when they consumed the Adequate Intake (AI) of choline. The damage was reversed when they consumed a high-choline diet. Plasma choline concentration has been found to vary in response to diet, decreasing approximately 30 percent in humans fed a choline-deficient diet for 3 weeks. Based on estimated dietary intakes and studies reporting liver damage with lower choline intakes, the Institute of Medicine, Food and Nutrition Board set the AI for choline at 425 milligrams/per day for women aged 19 and older, and 550 milligrams/per day for men aged 19 and older.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL220 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9435905 |
3013.0 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | GABAZOLAMINE Approved UseAlprazolam tablets are indicated for the management of anxiety disorder (a condition corresponding most closely to the APA Diagnostic and Statistical Manual (DSM-III-R) diagnosis of generalized anxiety disorder) or the short-term relief of symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. |
|||
Primary | TRILIPIX Approved UseINDICATIONS AND USAGE Trilipix is a peroxisome proliferator-activated receptor (PPAR) alpha agonist
indicated as adjunctive therapy to diet to:
• Reduce TG in patients with severe hypertriglyceridemia (1.1).
• Reduce elevated LDL-C, Total-C, TG and Apo B, and to increase HDLC
in patients with primary hypercholesterolemia or mixed dyslipidemia
(1.2).
Limitations of Use: Fenofibrate at a dose equivalent to 135 mg of Trilipix did
not reduce coronary heart disease morbidity and mortality in patients with
type 2 diabetes mellitus (5.1). Launch Date2008 |
|||
Primary | TRILIPIX Approved UseINDICATIONS AND USAGE Trilipix is a peroxisome proliferator-activated receptor (PPAR) alpha agonist
indicated as adjunctive therapy to diet to:
• Reduce TG in patients with severe hypertriglyceridemia (1.1).
• Reduce elevated LDL-C, Total-C, TG and Apo B, and to increase HDLC
in patients with primary hypercholesterolemia or mixed dyslipidemia
(1.2).
Limitations of Use: Fenofibrate at a dose equivalent to 135 mg of Trilipix did
not reduce coronary heart disease morbidity and mortality in patients with
type 2 diabetes mellitus (5.1). Launch Date2008 |
|||
Primary | TRILIPIX Approved UseINDICATIONS AND USAGE Trilipix is a peroxisome proliferator-activated receptor (PPAR) alpha agonist
indicated as adjunctive therapy to diet to:
• Reduce TG in patients with severe hypertriglyceridemia (1.1).
• Reduce elevated LDL-C, Total-C, TG and Apo B, and to increase HDLC
in patients with primary hypercholesterolemia or mixed dyslipidemia
(1.2).
Limitations of Use: Fenofibrate at a dose equivalent to 135 mg of Trilipix did
not reduce coronary heart disease morbidity and mortality in patients with
type 2 diabetes mellitus (5.1). Launch Date2008 |
PubMed
Title | Date | PubMed |
---|---|---|
Folate nutriture alters choline status of women and men fed low choline diets. | 1999 Mar |
|
Optimisation of the quantitative determination of chlormequat by matrix-assisted laser desorption/ionisation mass spectrometry. | 2001 |
|
In vivo 1H magnetic resonance spectroscopic measurement of brain glycine levels in nonketotic hyperglycinemia. | 2001 Apr |
|
Reproducibility of proton magnetic resonance spectroscopy imaging measurements of normal human hippocampus at 1.5 T: clinical implications. | 2001 Apr |
|
Preoperative proton MR spectroscopic imaging of brain tumors: correlation with histopathologic analysis of resection specimens. | 2001 Apr |
|
Lysosomal-type PLA2 and turnover of alveolar DPPC. | 2001 Apr |
|
Cloning of dimethylglycine dehydrogenase and a new human inborn error of metabolism, dimethylglycine dehydrogenase deficiency. | 2001 Apr |
|
Efficient synthesis of the cholinephosphate phospholipid headgroup. | 2001 Feb |
|
A novel method to analyze betaine in chicken liver: effect of dietary betaine and choline supplementation on the hepatic betaine concentration in broiler chicks. | 2001 Feb |
|
Magnetic coupling between water and creatine protons in human brain and skeletal muscle, as measured using inversion transfer (1)H-MRS. | 2001 Feb |
|
GD1a in phospholipid bilayer: a molecular dynamics simulation. | 2001 Feb |
|
Rumen undegradable protein, rumen-protected choline and mRNA expression for enzymes in gluconeogenesis and ureagenesis in periparturient dairy cows. | 2001 Feb |
|
Maintaining methylation activities during salt stress. The involvement of adenosine kinase. | 2001 Feb |
|
Chronic ingestion of ethanol stimulates lipogenic response in rat hepatocytes. | 2001 Feb 2 |
|
Menstrual cycle-related brain metabolite changes using 1H magnetic resonance spectroscopy in premenopausal women: a pilot study. | 2001 Feb 28 |
|
Three-dimensional magnetic resonance spectroscopic imaging of histologically confirmed brain tumors. | 2001 Jan |
|
Retarded myelination in the lumbar spinal cord of piglets born with spread-leg syndrome. | 2001 Jan |
|
Cannabinoid CB1 receptor-mediated inhibition of acetylcholine release in the brain of NMRI, CD-1 and C57BL/6J mice. | 2001 Jan |
|
Apical uptake of organic cations by human intestinal Caco-2 cells: putative involvement of ASF transporters. | 2001 Jan |
|
The use of bacterial choline oxidase, a glycinebetaine-synthesizing enzyme, to create stress-resistant transgenic plants. | 2001 Jan |
|
Agmatine uptake by cultured hamster kidney cells. | 2001 Jan 12 |
|
Overexpression of a mammalian ethanolamine-specific kinase accelerates the CDP-ethanolamine pathway. | 2001 Jan 19 |
|
Verbal and visual memory improve after choline supplementation in long-term total parenteral nutrition: a pilot study. | 2001 Jan-Feb |
|
Resveratrol inhibits the formation of phosphatidic acid and diglyceride in chemotactic peptide- or phorbol ester-stimulated human neutrophils. | 2001 Mar |
|
The puzzle of zmpB and extensive chain formation, autolysis defect and non-translocation of choline-binding proteins in Streptococcus pneumoniae. | 2001 Mar |
|
Expression of the INO2 regulatory gene of Saccharomyces cerevisiae is controlled by positive and negative promoter elements and an upstream open reading frame. | 2001 Mar |
|
Sustained bilateral hemodynamic benefit of contralateral carotid endarterectomy in patients with symptomatic internal carotid artery occlusion. | 2001 Mar |
|
Evaluation of accumulated mucopolysaccharides in the brain of patients with mucopolysaccharidoses by (1)H-magnetic resonance spectroscopy before and after bone marrow transplantation. | 2001 Mar |
|
De novo synthesis and recycling pathways of sphingomyelin in rat Sertoli cells. | 2001 Mar 9 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT01098383
Choline tablets will be taken at daily doses of 250 mg (in children with up to 40 kg body weight) and 500 mg (in children with more than 40 kg body weight).
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28152052
Monolayer cultures of Primary bovine hepatocytes were maintained for 24 h and were approximately 80% confluent before exposure to treatment. Cells were randomly assigned to increasing concentrations (61, 128, 2028, and 4528 μmol/L) of choline chloride (CC), DL-methionine (DLM), and a fatty acid cocktail in a 4X4X2 factorial arrangement. All treatments were applied in triplicate in independent preparations of cells from 4 Holstein calves.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:04:02 GMT 2023
by
admin
on
Fri Dec 15 15:04:02 GMT 2023
|
Record UNII |
6K2W7T9V6Y
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
CFR |
21 CFR 331.11
Created by
admin on Fri Dec 15 15:04:02 GMT 2023 , Edited by admin on Fri Dec 15 15:04:02 GMT 2023
|
||
|
FDA ORPHAN DRUG |
299909
Created by
admin on Fri Dec 15 15:04:02 GMT 2023 , Edited by admin on Fri Dec 15 15:04:02 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C76834
Created by
admin on Fri Dec 15 15:04:02 GMT 2023 , Edited by admin on Fri Dec 15 15:04:02 GMT 2023
|
PRIMARY | |||
|
6900
Created by
admin on Fri Dec 15 15:04:02 GMT 2023 , Edited by admin on Fri Dec 15 15:04:02 GMT 2023
|
PRIMARY | |||
|
DTXSID00889332
Created by
admin on Fri Dec 15 15:04:02 GMT 2023 , Edited by admin on Fri Dec 15 15:04:02 GMT 2023
|
PRIMARY | |||
|
983
Created by
admin on Fri Dec 15 15:04:02 GMT 2023 , Edited by admin on Fri Dec 15 15:04:02 GMT 2023
|
PRIMARY | |||
|
2451
Created by
admin on Fri Dec 15 15:04:02 GMT 2023 , Edited by admin on Fri Dec 15 15:04:02 GMT 2023
|
PRIMARY | RxNorm | ||
|
6K2W7T9V6Y
Created by
admin on Fri Dec 15 15:04:02 GMT 2023 , Edited by admin on Fri Dec 15 15:04:02 GMT 2023
|
PRIMARY | |||
|
m3481
Created by
admin on Fri Dec 15 15:04:02 GMT 2023 , Edited by admin on Fri Dec 15 15:04:02 GMT 2023
|
PRIMARY | Merck Index | ||
|
201-763-4
Created by
admin on Fri Dec 15 15:04:02 GMT 2023 , Edited by admin on Fri Dec 15 15:04:02 GMT 2023
|
PRIMARY | |||
|
C1505
Created by
admin on Fri Dec 15 15:04:02 GMT 2023 , Edited by admin on Fri Dec 15 15:04:02 GMT 2023
|
CONCEPT | Dietary Supplement | ||
|
100000085189
Created by
admin on Fri Dec 15 15:04:02 GMT 2023 , Edited by admin on Fri Dec 15 15:04:02 GMT 2023
|
PRIMARY | |||
|
1133536
Created by
admin on Fri Dec 15 15:04:02 GMT 2023 , Edited by admin on Fri Dec 15 15:04:02 GMT 2023
|
PRIMARY | |||
|
SUB13350MIG
Created by
admin on Fri Dec 15 15:04:02 GMT 2023 , Edited by admin on Fri Dec 15 15:04:02 GMT 2023
|
PRIMARY | |||
|
CHEMBL2105935
Created by
admin on Fri Dec 15 15:04:02 GMT 2023 , Edited by admin on Fri Dec 15 15:04:02 GMT 2023
|
PRIMARY | |||
|
6K2W7T9V6Y
Created by
admin on Fri Dec 15 15:04:02 GMT 2023 , Edited by admin on Fri Dec 15 15:04:02 GMT 2023
|
PRIMARY | |||
|
DBSALT001542
Created by
admin on Fri Dec 15 15:04:02 GMT 2023 , Edited by admin on Fri Dec 15 15:04:02 GMT 2023
|
PRIMARY | |||
|
87-67-2
Created by
admin on Fri Dec 15 15:04:02 GMT 2023 , Edited by admin on Fri Dec 15 15:04:02 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |